BETA: Please send your feedback!
Grupo Mexico
GMEXICOB-MX:MEX
Other Metals/Minerals
—
LARGE cap
(—)
—
since start of 2019
—
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 1
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 1997
Xencor, Inc. is a clinical stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases, asthma & allergic diseases and cancer. Its clinical sate XmAb technology is used for the treatment of IgG4-related disease; systemic lupus erythematosus; asthma & allergic diseases; acute myeloid leukemia; B-cell malignancies; and neuroendocrine tumors. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| Daniel Muiz Quintanilla, MBA | Chief Financial Officer, Secretary & Director | Male |
| Germn Larrea Mota-Velasco | Chairman, President & Chief Executive Officer | Male |
| Mauricio Ibaez Campos | General Director-Corporate Legal Affairs | Male |
| Miguel Valds Neaves | Director-Administration | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 1
Xencor - Competitors and Related Companies
How Xencor stacks up to its peers in the Biotechnology industry or with competing business segments.
Xencor
XNCR:NAS
Biotechnology
$2.07bn
SMALL cap
$36.60
(-2.19%)
-0.03%
since start of 2019
42.06
Loading…